The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Non-genetic influences on lipoprotein(a) concentrations
Open accessAbstract
An elevated level of lipoprotein(a) [Lp(a)] is a genetically regulated, independent, causal risk factor for cardiovascular disease. However, the extensive variability in Lp(a) levels between individuals and population groups cannot be fully explained by genetic factors, emphasizing a potential role for non-genetic factors. In this review, we provide an overview of current evidence on non-genetic factors influencing Lp(a) levels with a particular focus on diet, physical activity, hormones and certain pathological conditions. Findings from randomized controlled clinical trials show that diets lower in saturated fats modestly influence Lp(a) levels and often in the opposing direction to LDL cholesterol. Results from studies on physical activity/exercise have been inconsistent, ranging from no to minimal or moderate change in Lp(a) levels, potentially modulated by age and the type, intensity, and duration of exercise modality. Hormone replacement therapy (HRT) in postmenopausal women lowers Lp(a) levels with oral being more effective than transdermal estradiol; the type of HRT, dose of estrogen and addition of progestogen do not modify the Lp(a)-lowering effect of HRT. Kidney diseases result in marked elevations in Lp(a) levels, albeit dependent on disease stages, dialysis modalities and apolipoprotein(a) phenotypes. In contrast, Lp(a) levels are reduced in liver diseases in parallel with the disease progression, although population studies have yielded conflicting results on the associations between Lp(a) levels and non-alcoholic fatty liver disease. Overall, current evidence supports a role for diet, hormones and related conditions, and liver and kidney diseases in modifying Lp(a) levels.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Haskell, W. L., Alderman, E. L., Fair, J. M., Maron, D. J., Mackey, S. F., Superko, H. R., Williams, P. T., Johnstone, I. M., Champagne, M. A., & Krauss, R. M. (1994) · Circulation · doi:10.1161/01.cir.89.3.975 · Cited by 884 · cited 1×
“individualized risk reduction program, recommending a healthy diet, increased PA and an individualized endurance training program in men and women with CAD improved the overall lipid profile, reduced body weight, increased exercise capacity and reduced dietary fat intake, there was no change in the Lp(a) concentration…”
BackgroundReyes-Soffer, G., Ginsberg, H. N., Berglund, L., Duell, P. B., Heffron, S. P., Kamstrup, P. R., Lloyd-Jones, D. M., Marcovina, S. M., Yeang, C., Koschinsky, M. L., et al. (2022) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atv.0000000000000147 · Cited by 836 · cited 1×
“It is well established that elevated Lp(a) levels are an independent casual risk factor for cardiovascular diseases (CVD), including coronary artery disease (CAD), myocardial infarction (MI), and aortic valve stenosis [1].”
BackgroundSelf-citationSalpeter, S. R., Walsh, J. M. E., Ormiston, T. M., Greyber, E., Buckley, N. S., & Salpeter, E. E. (2006) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2005.00545.x · Cited by 640 · cited 1×
“A meta-analysis of studies conducted during 1966–2004 quantifying the effect of HRT in postmenopausal women documented an average of 25% reduction in Lp(a) levels [103].”
MethodPatel, A. P., Wang, M., Pirruccello, J. P., Ellinor, P. T., Ng, K., Kathiresan, S., & Khera, A. V. (2021) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.120.315291 · Cited by 567 · cited 2×
“While Lp(a) level predicted incident CVD in both men and women without any interaction, it was a stronger risk factor for CVD among those without diabetes mellitus than with diabetes mellitus [76].”
BackgroundBerglund, L., Lefevre, M., Ginsberg, H. N., Kris-Etherton, P. M., Elmer, P. J., Stewart, P. W., Ershow, A., Pearson, T. A., Dennis, B. H., Roheim, P. S., et al. (2007) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/86.5.1611 · Cited by 172 · cited 3×
“Collectively these two DELTA trials demonstrated opposite changes in Lp(a) and LDL-C in response to dietary SFA replacement [7,8].”
BackgroundMethodSelf-citationThe role of oxidized phospholipids in mediating lipoprotein(a) atherogenicity
Tsimikas, S., & Witztum, J. L. (2008) · Current Opinion in Lipidology · doi:10.1097/mol.0b013e328308b622 · Cited by 138
Healthy Dietary Interventions and Lipoprotein (a) Plasma Levels: Results from the Omni Heart Trial
Haring, B., Wyler von Ballmoos, M. C., Appel, L. J., & Sacks, F. M. (2014) · PLoS ONE · doi:10.1371/journal.pone.0114859 · Cited by 46
Cited by
Kronenberg, F., Mora, S., Stroes, E. S. G., Ference, B. A., Arsenault, B. J., Berglund, L., Dweck, M. R., Koschinsky, M., Lambert, G., Mach, F., et al. (2022) · European Heart Journal · doi:10.1093/eurheartj/ehac361 · Cited by 1,449
Self-citationA focused update to the 2019 NLA scientific statement on use of lipoprotein(a) in clinical practice
Koschinsky, M. L., Bajaj, A., Boffa, M. B., Dixon, D. L., Ferdinand, K. C., Gidding, S. S., Gill, E. A., Jacobson, T. A., Michos, E. D., Safarova, M. S., et al. (2024) · Journal of Clinical Lipidology · doi:10.1016/j.jacl.2024.03.001 · Cited by 328
Riley, T. M., Sapp, P. A., Kris-Etherton, P. M., & Petersen, K. S. (2024) · The American Journal of Clinical Nutrition · doi:10.1016/j.ajcnut.2024.06.019 · Cited by 22
Metadata
- Authors
- Enkhmaa, B., & Berglund, L.
- Venue
- Atherosclerosis
- Publisher
- Elsevier BV
- Published
- 2022-05
- Volume
- 349
- Pages
- 53-62
- ISSN
- 0021-9150 (ISSN-L)
- OpenAlex
- W4281257482
- Cited by
- 193
- References
- 7
- FWCI
- 32.22
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Non-genetic influences on lipoprotein(a) concentrations. https://app.cochat.ai/papers/10.1016/j.atherosclerosis.2022.04.006
- The paper
- Enkhmaa, B., & Berglund, L. (2022). Non-genetic influences on lipoprotein(a) concentrations. Atherosclerosis. https://doi.org/10.1016/j.atherosclerosis.2022.04.006
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.